Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Augusta University
With
University of Georgia
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have acute myeloid leukemia (AML) and are candidates for consolidation chemotherapy with high dose cytarabine (HiDAC) after successful remission induction chemotherapy
Both male and female
Age 18 years and older
You may not be if
Patients who have already developed febrile neutropenia during their hospitalization for their consolidative cycle of chemotherapy will not be eligible for monitoring for that cycle; however, these patients will be able to participate in subsequent cycle if they do not develop febrile neutropenia during their subsequent HiDAC hospitalization.
If a patient is admitted to the hospital between cycles of chemotherapy for reasons other than febrile neutropenia or its sequelae, they will be taken off study for that cycle and data not collected while they are admitted